← All trials
NCT04844125
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Apr 14, 2021
- Last posted
- Jun 21, 2021
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.